Loading...

Home
ETF
HURA

HURA

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

HURA News

TuHURA Appoints New SVP of Clinical Operations

Apr 07 2026PRnewswire

TuHURA Biosciences Reports FY Net Loss of $30.05 Million

Apr 01 2026seekingalpha

TuHURA Biosciences Reports Strong 2025 Financial Results and Strategic Developments

Apr 01 2026PRnewswire

TuHURA Biosciences Appoints New CMO to Drive Oncology Strategy

Mar 23 2026PRnewswire

TuHURA Biosciences Regains Nasdaq Compliance

Feb 27 2026PRnewswire

TuHURA Biosciences Regains Nasdaq Compliance

Feb 27 2026Newsfilter

TuHURA Biosciences to Participate in Upcoming Investor Conferences

Feb 24 2026PRnewswire

TuHURA Biosciences to Participate in Upcoming Investor Conferences

Feb 24 2026Newsfilter

TuHURA Files IND for TBS-2025 in AML Treatment

Feb 17 2026PRnewswire

TuHURA Biosciences to Present at Oppenheimer Healthcare Conference

Feb 12 2026PRnewswire

TuHURA Biosciences Receives Orphan Drug Designation for IFx-2.0

Feb 03 2026stocktwits

TuHURA Biosciences Receives FDA Orphan Drug Designation

Feb 02 2026Newsfilter

TuHURA Receives FDA Orphan Drug Designation

Feb 02 2026PRnewswire

TuHURA Biosciences Releases 1.54M Shares to Kintara CVR Holders Following Clinical Trial Success

Dec 15 2025PRnewswire

TuHURA Biosciences Advances Phase 3 Trial of IFx-2.0 for Merkel Cell Carcinoma

Dec 11 2025PRnewswire

Post-Market Surge: Stoke Therapeutics, Alpha Tau Medical, and Compass Pathways Top Biotech Gainers

Dec 10 2025NASDAQ.COM